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Maximum Likelihood Estimation of the Prevalence of Nonlethal 
Neoplasms—An Application to Radon-Daughter 
Inhalation Studies1 
D . C H M E L E V S K Y A N D A . M . K E L L E R E R 2 
Institut für Medizinische Strahlenkunde der Universität Würzburg, Versbacher Str. 5, D-8700 
Würzburg, Germany 
J . L A F U M A 
Commissariat ä l'Energie Atomique, Service de Radiopathologie et de Toxicologic Experimentale, 
B.P. 6, F-92260 Fontenay-aux-Roses, France 
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J . C H A M E A U D 
Commissariat ä l'Energie Atomique, Service Medical, B.P. 1, F-87640 Razes, France 
CHMELEVSKY, D., K E L L E R E R , A. M., LAFUMA, J. , AND CHAMEAUD, J. Maximum Like-
lihood Estimation of the Prevalence of Nonlethal Neoplasms—An Application to Radon-
Daughter Inhalation Studies. Radiat. Res. 91, 589-614 (1982). 
A nonparametric maximum likelihood method for estimating prevalence is described that 
is applicable to the analysis of nonlethal tumors which are discovered incidentally in either 
sacrificed animals or animals dead from other causes. The method corrects for competing risks 
and does not require an analytical model for the prevalence as a function of dose and time. 
It is applied to the results of an experiment in which numerous groups of Sprague-Dawley 
rats were exposed to different doses of radon daughters at different dose rates. The dependence 
of the prevalence on dose and time after exposure is derived, and three basic models are 
considered that correspond to a dose-dependent shift in time, to an acceleration in time, and 
finally to the proportional hazards model. Mortality-corrected risk estimates are derived from 
the estimated prevalences. At doses down to 65 WLM (working level months) the results are 
consistent with linearity in dose, or possibly with sublinearity (dose exponent less than 1); they 
exclude, in this dose range, a threshold or a proportionality to a higher power of dose. 
INTRODUCTION 
Considerable efforts have been made at a number of laboratories to assess pul-
monary tumors due to inhaled radioactive substances. Recent reports (7-5) attest 
to the broad range of such investigations. They also demonstrate the difficulties 
1 Work partly supported by Euratom Contracts 099-76-1-PSA F and 208-76-BIO D. 
2 Author to whom correspondence should be addressed. 
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inherent in these studies and emphasize large uncertainties of the risk estimates 
and the dose-effect relations. 
The complexities arise largely from the multitude of different factors involved 
in these studies. Also an important problem is the lack of mathematical methods 
to separate the effect of life shortening in the survival experiments from the in-
duction of pulmonary tumors. In the analysis of lethal cancers or cancers that can 
be readily discovered in the live animal, it is common practice to use the proper 
competing-risk-corrected quantities, for example, the Kaplan-Meier estimate (4). 
With nonlethal diseases, such as radon-induced pulmonary tumors in Sprague-
Dawley rats, the situation is different; dose-effect relations are either reported for 
life shortening alone or, i f a dose-effect relation is given for the neoplastic process, 
it is based on incidences uncorrected for life shortening. The failure to utilize a 
competing-risk-corrected analysis is striking since Hoel and Walburg (5) considered 
the problem in depth almost a decade ago and pointed out that isotonic regression 
can take the place of the Kaplan-Meier estimate in the analysis of nonlethal diseases 
in survival experiments. 
The objective of the present article is to demonstrate that the method recom-
mended by Hoel and Walburg is applicable to inhalation studies and to show that 
it can be considerably extended. The method wi l l be exemplified by its application 
to radon-daughter inhalation studies that are part of the broader range of inhalation 
investigations at the Commissariat ä l'Energie Atomique (6-8). The separate con-
sideration of the radon studies has the advantage that complicating factors such 
as chemical state or particulate size need not be considered and that, accordingly, 
the emphasis can be on the essentials of the numerical methods. 
MATERIALS AND METHODS AND BACKGROUND OF T H E EXPERIMENTAL WORK 
Experimental work on the carcinogenic action of inhaled a emitters began at 
the Commissariat ä l'Energie Atomique in 1969. Research was performed mainly 
on male rats of the Sprague-Dawley S.P.F. (specific-pathogen free) and the Wistar 
A.G. inbred strains. The investigations were directed at two main objectives. The 
first was the assessment of the effects of the decay products of radon (9, 70), a 
problem particularly relevant to the mining of uranium; the second was the inves-
tigation of effects of the actinides that are of concern in reactor fuel reprocessing 
plants (77, 72). 
When the experimental program began, the carcinogenic effect of radon on 
rodents was unknown. For this reason doses and exposure times differed widely in 
the initial experiments. Wi th the intent to reach broader conclusions on basic 
mechanisms, the studies were subsequently extended to include investigations on 
the influence of factors such as sex or age at the start of inhalation (7). Experiments 
were also performed on the combined action of various cofactors which were ex-
pected to counteract the neoplastic processes, such as bleomycin, or to enhance i t , 
such as tobacco smoke, dust, or various chemical compounds (13-16). For the 
present analysis none of the more complex investigations were utilized. 
Even the radon-daughter experiments encompassed a wide range of experiments 
performed over the last 10 years at the laboratory of experimental pulmonary 
pathology in Razes that is directed by J. Chameaud (9, 70, 77, 18). The inhalation 
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prqcedure has been described earlier (19). In summary, male Sprague-Dawley 
rats, 90 days old at the beginning of the experiments, were kept in an inhalation 
chamber with radon concentration at the desired levels. They were exposed to radon 
and its daughter products at the concentrations and for the durations specified in 
each individual experiment. There were 2- to 16-hr exposures two to five times a 
week. The experimental conditions were such that equilibrium of radon with its 
short-lived daughters existed. Table I gives parameters for individual experiments. 
In the first column the total inhalation doses and the monthly doses are listed. In 
columns 2 to 5 the daily durations of exposure to radon daughters, the weekly 
frequencies of the exposures, the total durations of the inhalation periods, and the 
radon-daughter concentrations are given. In columns 6-10 the total number of 
animals in a group, the number of animals examined, and the number of animals 
with pulmonary malignancies are given. The number of sacrificed animals and 
sacrificed animals with pulmonary malignancies are given in the last column. A l l 
times quoted in the following are to be understood as times from start of inhalation 
exposure. 
In view of the difficult estimation of absorbed dose (20), the dose is given in 
conventional form as the product of concentration and exposure time. The unit 
working level month ( W L M ) is utilized. One working level is defined as a con-
centration of radon daughters which results in the ultimate release of 1.3 X 105 
MeV of a energy per liter of air; i t is equivalent to a concentration of 0.1 nCi radon 
(3.7 Bq) per liter of air in equilibrium with its four short-lived daughter products 
(7, 20). The time unit working month was defined as 170 hr. The unit W L M 
corresponds to 3.54 X 10~3 J m~ 3 hr. 
The pathological classification followed a method described in earlier articles 
(27, 22). The pulmonary cancers were recorded as bronchogenic (type 1 in Table 
I ) or bronchoalveolar (type 2 in Table I ) according to histological criteria proposed 
by Masse (22). Epidermoid carcinomas and adenocarcinomas were, in view of the 
bronchic origin of their cells, given the joint pathological classification of bron-
chogenic cancers. For cancers with cells of more peripheral origin a common clas-
sification of bronchoalveolar carcinomas was used. Nontumorous histological 
changes were classified as adenomatosis, and benign tumors were classified as ad-
enomas. Adenomatosis was very frequent in older animals, even in the nonexposed 
group; it is not considered in this study. For each cell type only the most severe 
lesion was recorded, even i f other lesions were present. 
In the following analysis only malignant tumors, without regard to their patho-
logical type, are considered. I t is felt that the distinction between adenomas and 
the malignant neoplasms is sufficiently well defined. In addition animals with ad-
enomas only are a minor fraction (~15%) of all animals with neoplasms. 
The spontaneous incidence of pulmonary malignancies in Sprague-Dawley rats 
is not well known. A review of data from various laboratories leads to an estimate 
between 10~3 and 5 X 10~3. The exact numerical value is not very critical for the 
present analysis; we have chosen the estimate of 3 X 10 - 3 . This agrees with the 
data of Sanders and Mahaffey (23) and is consistent with the observation of Mart in 
et al. (24) who found no pulmonary tumors in a life span observation of 485 
Sprague-Dawley rats. 
T A B L E I 
Summary of Protocols of the Radon-Daughter Inhalation Experiments 
Dose Daily Radon - No. of No. of No. of No. of sacrificed 
(Dose per duration No. of Total daughter No. of animals with animals with animals with animals (No. 
month) of inhalation inhalations duration concentration No. of animals pulmonary malignancy malignancy with pulmonary 
(WLM) (hr) per week (months) (WL) animals examined malignancy of type I of type 2 malignancy) 
0 0 0 0 0 186 159 0 0 0 0 
65 (50) 2 3 1.2 360 500 490 13 7 6 0 
170 (110) 3 4 1.5 390 294 244 11 9 5 4 
290 (45) 5 5 6 75 81 80 2 1 1 66 (2) 
860 (1500) 5 5 0.6 2,500 20 17 4 2 2 0 
1,470 (1500) 5 5 0.9 2,500 30 29 5 2 3 12 (0) 
3,000 (1500) 5 5 1.9 2,500 40 39 17 4 13 2(1) 
4,500 (1500) 5 5 2.9 2,500 49 48 25 15 14 11 (0) 
9,250 (1500) 5 5 5.8 2,500 20 15 5 5 0 0 
2,250 (4600) 16 4 0.5 3,000 25 21 7 4 3 0 
3,700 (4600) 16 4 0.8 3,000 25 20 8 8 I 0 
3,900 (1800) 6 4 2 3,000 50 48 16 15 1 0 
5,400 (4600) 16 4 1.1 3,000 25 23 6 5 1 0 
6,000 (2400) 7 5 2.3 3,000 35 35 9 6 4 0 
7,000 (4600) 4 4 1.5 12,000 181 171 34 28 6 97 (12) 
7,000 (7000) 5 5 0.9 12,000 33 14 3 3 0 0 
8,000 (3000) 10 4 2.6 3,000 180 164 65 51 20 45 (22) 
14,000 (4600) 4 4 2.9 12,000 79 72 1 1 0 12(1) 
o 
X 
m r m < 
m 
H 
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An important question in the experimental studies of pulmonary neoplasms in 
animals is whether malignant neoplasms cause life shortening. In mammals with 
life spans much longer than the latency growth times of malignant neoplasms 
(primates, dogs) lethality is marked. There was no evidence of life shortening in 
our Sprague-Dawley rats, and there have been only a few cases where the death 
of an animal appeared to be related to a pulmonary tumor. As a rule, malignant 
neoplasms affect only limited parts of the lung tissue; furthermore, less than 1% 
of pulmonary malignancies were found to give rise to metastases. 
Nevertheless, a pulmonary tumor could be lethal in different ways. An animal 
might be asphyxiated by a tumor of excessive size, or a tumor in a particular 
location might block the upper airways. In experiments where inhalation of plu-
tonium was combined with benzo[a]pyrene given intratracheal^, large tumor sizes 
were frequently obtained (25) and cases of asphyxiation were ascertained upon 
autopsy. Similar tumor sizes were never reached in experiments with radon in-
halation alone. 
Finally, a tumor could cause massive hemorrhage or might secrete toxins. None 
of these various possibilities have been observed in the radon experiments. The 
failure to find any instance of blocked upper airways or of internal hemorrhage is 
consistent with the fact that most pulmonary tumors in the Sprague-Dawley rat 
are peripheral. Finally, no direct evidence exists for Sprague-Dawley rats, but 
experiments with grafts of pulmonary tumors to Wistar rats (26) have led us to 
the conclusion that the tumors do not secrete toxins that may contribute to mor-
tality. 
The experimental data do not indicate an increased prevalence of pulmonary 
malignancies in nonsacrified dead animals. However, a meaningful comparison is 
possible only in two groups where sufficient numbers of sacrifices and deaths from 
other causes occur within certain intervals. In the group of 181 animals exposed 
to 7000 W L M between Days 400 and 500 i t was found that 9 of 26 sacrificed 
animals had pulmonary malignancies; for the deaths from other causes this ratio 
was 5 to 27. In the group exposed to 8000 W L M after Day 600 there were 22 
animals with malignancy among 45 sacrificed animals; the ratio for the other deaths 
was 22 to 41. 
In view of these considerations, independence between pulmonary tumors 
and mortality appears to be an acceptable hypothesis for the purpose of the 
present study. 
CONVENTIONAL ANALYSIS 
This section gives numerical results obtained from a conventional analysis to 
facilitate the understanding of the subsequent section that deals with the more 
rigorous mortality-corrected analysis. 
In the subsequent analysis only pulmonary malignancies—according to the cri-
teria stated in the preceding section—are considered. The relevant information for 
each animal is then, apart from dose and duration of exposure, the time of its death 
and the presence or absence of a pulmonary malignancy. A more detailed treatment 
that discriminates between different types of pulmonary tumors is given in A p -
pendix A. 
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F I G . 1. The mean lifetime, with standard error, in each group as a function of inhalation dose. Data 
from sacrificed animals are not included. The partition between low dose rates and high dose rates is 
set at 1600 WLM/month. 
Figures 1-3 give results of a conventional analysis; the sacrificed animals (total 
number = 249) were excluded. Figure 1 represents, as a function of inhalation dose, 
the lifetime and its standard error in the individual groups; animals that could not 
be examined were also included. In this, as in subsequent figures, different symbols 
are used for the groups exposed to less than 1600 W L M / m o n t h and those exposed 
to more than 1600 W L M / m o n t h . This serves merely as a visual aid to distinguish 
results from "moderate dose rates" and "high dose rates." The distinction has no 
influence on the computations. 
Figure 2 gives, separately for each group, the fraction of animals dead up to the 
specified time and the fraction of animals dead with a pulmonary malignancy. 
Figure 3 gives the raw incidence of malignancies as a function of inhalation dose, 
i.e., the ratio of animals dead with pulmonary malignancy to the number of ex-
amined animals in a group. These data are based only on animals that were ex-
amined, and sacrificed animals were excluded since the temporal distribution of 
the sacrifices could seriously bias the results. The term "raw incidence" is used to 
emphasize the fact that this quantity is not corrected for life shortening. Without 
such a correction it is unclear whether the decline of the incidence at higher doses 
was exclusively due to life shortening, or whether there was also an inherent decline 
of the induction of pulmonary malignancies at high doses. 
COMPETING-RISKS-CORRECTED ANALYSIS 
The Problem of Fully Censored Data 
To allow for competing risks the Kaplan-Meier estimate (4, 27) or similar es-
timates (28) are appropriate in the analysis of lethal diseases. These methods are 
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equally applicable i f a tumor is not lethal, but its time of appearance can be 
determined; an example is the study of mammary neoplasms (29). Under these 
conditions one speaks of right censored data; i.e., times to the tumor are either 
known or are known to exceed an observed time when an animal, still without 
tumor, has been lost for unrelated reasons. For nonlethal diseases that can be 
discovered only incidentally in a dead animal, the data are times, th of death with 
or without the disease present. The time to the effect is known to be smaller or 
TIME /days TIME / days 
F I G . 2. The fraction of animals dead without (single-shaded area) and with (double-shaded area) 
pulmonary malignancies as a function of time in the different experimental groups. These calculations 
are based on animals with pulmonary diagnostics; they do not include sacrificed animals. 
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the number of animals dead with pulmonary malignancy to the total number of animals. Sacrificed 
animals and animals without pulmonary diagnostics have been excluded. The standard errors are based 
on the binomial distribution. The partition between low and high dose rates is set at 1600 WLM/month. 
larger than tt\ i t is never actually known. One may therefore speak of fully censored 
data? The mathematical analysis of such data involves the estimation of the prev-
alence of the disease as a function of time. The prevalence at a given age can most 
readily be determined by serial killing experiments, but as pointed out by Hoel and 
Walburg (5), the analysis can also be performed from survival experiments, pro-
vided the mortality rate is not influenced by the disease under study. Partially 
lethal diseases present a gray area where the estimation of prevalences from survival 
experiments is difficult or impossible. 
The presence of a pulmonary tumor is determined upon necropsy in sacrificed 
animals, or in animals that died from other causes. Since independence of pul-
monary tumors and of mortality is assumed, no distinction needs to be made between 
these two cases; dead animals, whether sacrificed or not, can be considered as 
random representatives of the animals at the specified time. 
Before a discussion of the numerical methods, it is necessary to define the basic 
quantities which wil l be used. The definitions are in agreement with those in the 
report of the United Nations Scientific Committee on the Effects of Atomic Ra-
diation (31). These definitions apply whether one deals with lethal or nonlethal 
diseases. 
The tumor rate, r(t), is the probability per unit time of an animal to develop a 
tumor at time /; in mathematical statistics this or analogous functions are termed 
hazard functions. 
The cumulative tumor rate, R(t), is the integral of the tumor rate up to 
time t: 
3 The term doubly censored data (left and right censored) has also been used (30); however, the 
expression fully censored appears more appropriate to a situation where there are no exact observations. 
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R(t)= P r(t')dt'. (1) 
Jo 
The prevalence, P(t), is the probability that an animal bears a tumor at 
time t. 
Of the three only P(t) can be obtained directly in the present case; however, R(t) 
or r(t) can be inferred indirectly. For this purpose one may express the prevalence 
in terms of the cumulative tumor rate, R(t): 
P(t) = 1 - e x p ( - # ( 0 ) . (2) 
R(t) is always larger than P(t), and it can exceed 1; at values of R(t) much smaller 
than 1 there is approximate numerical equality between P(t) and R(t). 
Maximum Likelihood Estimate of the Prevalence 
As stated, there are familiar methods for estimation of the prevalence in the case 
of right censored data (4, 5). These methods can be based on maximum likelihood 
considerations (52); however, they are sufficiently simple to be intuitively under-
standable without consideration of their theoretical basis. 
In contrast, the estimation of the prevalence for fully censored data is straight-
forward only i f one restricts the analysis to one preselected time when all surviving 
animals are sacrificed and examined for pulmonary tumors. Ullr ich et al. (33) have 
used this approach in large-scale experiments that compare the prevalence or the 
mean number of pulmonary tumors in R F M / u n mice 9 months after exposure to 
X rays or fission neutrons. The simple solution can, in principle, also be applied 
when the analysis is aimed at the assessment of the time dependence of the tumor 
prevalence; however, i t requires serial sacrifice of animals so that there are enough 
necropsies in each preselected time interval. P(t) is then estimated as the observed 
fraction of tumor-bearing dead animals in a time interval. The limitation of this 
method is its costliness due to the large number of animals required. Experiments 
of this type [e.g., see (34)] are therefore rare. In the present study, 17 groups of 
animals were exposed to different doses with different durations of exposure. The 
total number of animals was roughly 1700; it is evident that a far greater number 
of animals would be required i f the prevalence were to be estimated separately for 
each group. However, it wi l l be seen that maximum likelihood methods permit 
estimates even from experiments with small groups of animals. 
Let (t (i = 1, 2, . . . , / ) be the times of death of those animals that are found 
to carry a tumor and let tj (j' = 1, 2, . . . , / ) be the times of death of those 
animals that are found to be tumor free. The likelihood, A, is defined as the prob-
ability for the actual outcome, conditional on the times of deaths and on the prev-
alence function P(t): 
A = n / > ( * + ) - n o - / > ( * / ) ) . (3) 
«=i j=\ 
For numerical calculations, i t is more convenient to use the log-likelihood: 
In A = L = 2 In (/>(/+)) + 2 In (1 - P(tj)). (4) 
/=! 7=1 
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F I G . 4. Estimates of the prevalence of pulmonary malignancies from isotonic regression based on the 
combined data from life-span and sacrificed animals. 
In Eqs. (3) and (4) i t is assumed that all times t? and tj are individually resolved. 
I f multiple deaths occur at a time, a more complicated relation, corresponding to 
the general binomial case, applies; it is given in Appendix B. 
One can calculate the theoretical function P(t) that maximizes the log-likelihood. 
A condition for the solution is that the prevalence does not decrease in time. Wi th 
this constraint of monotonicity there exists a relatively simple algorithm to obtain 
P(t). The method, termed isotonic regression (55), has been applied by Hoel and 
Walburg (5) to radiation carcinogenesis studies. 
Figure 4 gives the results of the isotonic regression for the 17 groups of the 
present experiment. In view of the small size of some of the groups it is not surprising 
that the shapes of the estimated curves vary widely. This type of analysis is therefore 
of limited value for a quantitative comparison and for the construction of dose-
effect relations. A more efficient method is required that imposes additional con-
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straints on the set of possible solutions. Such a method consists in postulating one 
underlying prevalence function (baseline function) that is assumed to vary with 
inhalation dose in a manner that depends on a chosen model. Inevitably the ut i-
lization of a model wi l l introduce a degree of arbitrariness. To judge the bias that 
may be introduced in this way, three models wi l l be applied and compared that 
have been considered in the mathematical theory of survival data. 
The maximum likelihood method wi l l be utilized in the present work in a modified 
form that leads to smooth curves. The monotonicity constraint is, for this reason, 
replaced by a convexity constraint (see Appendix B). An inconvenience of the 
convexity constraint is the requirement of a nonlinear optimization algorithm that 
takes the place of the simpler computation for isotonic regression; however, the 
more complex algorithm wi l l in any case be required in the simultaneous maximum 
likelihood analysis of several experimental groups. 
SIMULTANEOUS MAXIMUM LIKELIHOOD ANALYSIS 
Three Models for the Dose Dependence of the Prevalence 
Of the three models which wi l l be considered, one—the shifted time model—has 
been suggested in studies of life shortening (36) and tumorigenesis (29, 37) after 
irradiation. The other two have been utilized in survival analysis and reliability 
studies (32) and in clinical and experimental investigations of cancer treatment 
(38, 39). The shifted time model postulates that the prevalence function, PD(t) is 
shifted toward earlier times in animals exposed to a dose D: 
PD(t) = P(t + s(D)), (5) 
where s(D) is the dose-dependent shift factor. 
The second distinct but related model assumes that the prevalence in the exposed 
animals changes in a way that corresponds to an acceleration of time: 
PD(t) = P(a(D)-t), (6) 
where a(D) is the acceleration factor, also dependent on dose. In the statistical 
theory of survival analysis Eq. (6) is termed the accelerated failure time 
model (32). 
The third, the proportional hazards model, postulates that the tumor rate, r(t), 
and therefore also the cumulative tumor rate, R(t), change by a dose-dependent 
factor \(D): 
RD(t) = \(D).R(t). (7) 
This model has been most extensively studied [see (32)] and is widely used with 
right censored data. Cox (40) has obtained a remarkably simple solution for the 
simultaneous maximum likelihood fit to such data; accordingly, this model is also 
referred to as Cox's model. 
I t wil l be sufficient to consider the accelerated failure time model in detail; the 
corresponding equations for the other models are cited in Appendix B. The log-
likelihood in the accelerated failure time model is 
K lk Jk 
L = 2 [ 2 In P(ak • ttk) + 2 In (1 - P{ak • tjk))], (8) 
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where 
ttk = time of death of animal i (i = 1, . . . , Ik) with malignancy in group k 
(k = 1, . . . , K\ 
tjk time of death of animal j (J' = 1, . . . , Jk) without malignancy in group k 
= ( * = l , . . . , / 0 , 
K - the number of groups. 
The numerical optimization procedure yields the baseline function P(f) and the! 
acceleration factors ak for the K groups. No analytical expression is postulated for; 
P(i). However, to ensure a smooth function convexity of In P(t) from above is used 
as a constraint. 
Results of the Simultaneous Analysis \ 
For each of the three models, the simultaneous maximum likelihood fit has been 
performed with the 17 exposed groups. The control group was excluded because 
no pulmonary malignancy had been observed in this group. The optimization pro-; 
cedure utilizes the method of steepest descent in a general-purpose computer pro-! 
gram for nonlinear optimization developed by Abadie and Guigou. In an earlier 
publication dealing with the nonparametric fitting of dose-effect relations (41\ the 
characteristic features and requirements of such optimization programs have been 
discussed. Therefore only essential information relevant to the present case is given! 
in Appendix B. 
For each of the three models, the maximum likelihood computation yields a best-
fit prevalence function and a set of parameters [s(D), a(D), and X(D) in Eqs. (5) 
to (7)] for the individual groups. Figure 5 represents the results. I n each individual 
panel the histogram gives the fraction of animals that have died in the specified! 
time interval either without pulmonary malignancy (blank) or with malignancy! 
(shaded columns). The three curves on each panel give the estimated prevalences 
for the group according to the three models. These estimated prevalences are ex-j 
tended beyond the range of observed data in the individual panels. This is done for! 
a better indication of the characteristic differences among the three models, and! 
also because the inferred prevalence functions are utilized in the subsequent section 
for the construction of dose-effect relations. 
The largest value of the combined likelihood corresponding to Eq. (8) ( L 
= -448.2) is obtained for the accelerated failure time model, but the values for! 
the shifted time model (L = -449.2) and the proportional hazards model (L 
= -448.6) are similar. From Fig. 5 one concludes that, in spite of characteristic 
differences of the prevalence functions and their variation with inhalation dose, 
these functions are similar for the relatively narrow time ranges with actual data 
in the individual groups. In the subsequent section it wi l l furthermore be found 
that incidences computed on the basis of the prevalence functions from the three 
models are similar, i.e., that the choice of the model is not critical for the resulting 
risk estimates. On the other hand, one would have to design experiments with a 
wider range of death times at each dose i f a discrimination between models were 
to be attempted. For moderate doses this might require more early sacrifices; for 
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high doses, where life shortening is substantial, large initial numbers of animals 
could be required with pulmonary diagnostics performed predominantly in animals 
that live relatively long. 
Derivation of Mortality-Corrected Incidences 
As stated earlier, the raw incidences do not represent a true dose dependence 
for the carcinogenic effect at dose levels where life shortening is substantial. I t is 
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therefore desirable to compute a mortality-corrected quantity. One possibility is 
to define an adjusted incidence, I D , as the probability of the animals incurring a 
malignancy, provided the mortality rates were those of the controls. The formal 
statement of this definition is 
m(t)-PD(t)dt, (9), 
0 
where m(t) is the fraction of the control population dying per unit time interval 
at time t. The value tmax = 850 days has been taken as the maximum survival time. 
In Fig. 6 the adjusted incidences are given for all three models. The incidences for 
the exposed groups are plotted in Fig. 6 as excess over the assumed small control 
incidence of 0.003. 
The adjusted incidences from the accelerated failure time model and their stan-
dard errors (see Appendix B) are compared to the raw incidences in Table I I . This 
table also contains the acceleration factors ak that correspond to the prevalence 
functions in Fig. 5. In the computations the baseline function, P(t), is defined only 
up to an arbitrary factor in time, and, conversely, the acceleration factors are 
defined only up to the same common factor. However, the normalization has been 
chosen so that P(t\ i.e., the assumed prevalence for the controls (a = 1), yields 
the incidence 0.003. 
I t is of interest whether these results would fit a simple power function at low 
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F I G . 6. Comparison of the adjusted incidences lD (minus control incidence of 3 X 10~ 3) as a function 
of the inhalation dose for the three basic models (ST: shifted time model; AT: accelerated time model; 
PH: proportional hazards model). The open symbols are used for the low-dose-rate range (<1600 W L M / 
month) and the solid symbols for the high-dose-rate range (>1600 WLM/month). Standard errors for 
all groups are given in Table II. 
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T A B L E II 
Comparison of Raw and Adjusted Incidences and Maximum Likelihood Estimates of Parameters 
for the Accelerated Failure Time Model 
Dose D 
(dose per month) Adjusted Acceleration 
(WLM) Raw incidence incidence fD factor ak 
65 (50) 0.027 ± 0.007 0.025 (0.018-0.042) 1.30 (1.24-1.45) 
170 (110) 0.046 ± 0.011 0.038 ±0.011 1.48 ± 0.10 
290 (45) 0 (+0.12) 0.065 ± 0.06 1.68 ± 0.39 
860 (1500) 0.24 ±0 .10 0.18 ± 0.07 2.20 ± 0.25 
1,470 (1500) 0.29 ± 0.11 0.26 ± 0.07 2.45 ± 0.23 
3,000 (1500) 0.43 ± 0.08 0.47 ± 0.08 3.25 ± 0.49 
4,500 (1500) 0.68 ± 0.08 0.54 ± 0.05 3.75 ± 0.52 
9,250 (1500) 0.33 ± 0.12 0.58 ± 0.07 4.2 ± 0.78 
2,250 (4600) 0.33 ± 0.10 0.35 ± 0.09 2.73 ± 0.25 
3,700 (4600) 0.40 ± 0.11 0.51 ± 0.10 3.51 ± 0.71 
3,900 (1800) 0.33 ± 0.07 0.39 ± 0.06 2.86 ± 0.22 
5,400 (4600) 0.26 ± 0.09 0.48 ± 0.07 3.18 ± 0.31 
6,000 (2400) 0.26 ± 0.07 0.43 ± 0.07 3.03 ± 0.25 
7,000 (4600) 0.30 ± 0.05 0.51 ± 0.04 3.50 ± 0.24 
7,000 (7000) 0.21 ± 0.11 0.39 ± 0.08 2.85 ± 0.26 
8,000 (3000) 0.36 ± 0.04 0.50 ± 0.05 3.45 ± 0.35 
14,000 (4600) 0 (+0.03) 0.26 ± 0.08 2.45 ± 0.26 
inhalation doses. However, this requires a somewhat arbitrary selection of a dose 
cutoff. A regression with the data below 1000 W L M results in the fit 
ID = kDp, (10) 
with 
k = 3.4 X 10~4 ± 1.4 X 10" 4 and p = 0.92 ± 0.07. 
The value of k holds i f D is in the units W L M . 
I t is evident from this result, and in particular from the observation at 65 W L M , 
that a sublinearity at low doses cannot be excluded, even though linearity cannot 
be rejected on the basis of the present data. On the other hand, a power in dose 
substantially in excess of 1 can be rejected. 
I f one assumes a linear dose dependence (p = 1), the linear regression yields the 
relation 
I D = c-D with c = 2 . 0 X 1 0 " 4 ( ± 0 . 5 X 1 0 " 4 ) / W L M ( n ) 
= 0.056 ( ± 0 . 0 1 4 ) / ( J n T 3 hr). 
I D is not the only meaningful quantity for the construction of a dose-effect 
relation. I t has been variously emphasized in studies of radiation risks (42, 43) that 
a realistic assessment of detriments would have to be based not on numerical 
incidences but on the loss of tumor-free life. Radiation-induced malignancies that 
appear late in life contribute less to the decrement than early malignancies. Ac-
cordingly, it is of interest to compute a modified quantity, J D , that represents the 
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average loss of tumor-free life span. Such a quantity that has been utilized in 
studies of mammary tumors in Sprague-Dawley rats (29, 37) has been termed 
effect period in the report of U N S C E A R (57). The definition of U N S C E A R does 
not include the mortality correction. Such a correction wi l l be applied, and the 
quantity effect period is then defined as 
JD= fW M(t)-PD(t)dt, (12) 
Jo 
where M(t) is the proportion of controls surviving at time /. 
Figure 7 gives the numerical values of JD. There is less agreement between the 
different models for this quantity than for the adjusted incidences, I D . 
CONCLUSIONS 
The conventional analysis of the radon-daughter inhalation data permits the 
estimation of the dose dependence of life shortening and the dose dependence of 
the incidence of pulmonary tumors, uncorrected for life shortening. However, at 
higher doses the uncorrected incidence decreases due to life shortening. Maximum 
likelihood methods are required for the derivation of corrected incidences. 
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F I G . 7. The effect period JD (see text) as a function of inhalation dose for the three basic models. 
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A further limitation of the conventional analysis results from the impossibility 
I of mixing data from life-span experiments with data from sacrificed animals. In-
I elusion or exclusion of the data from the sacrificed animals can, depending on the 
temporal distribution of sacrifices, have considerable influence on the results. For 
this reason, too, the analysis of the radon-daughter inhalation experiments was 
based on maximum likelihood methods. 
The investigation of nonlethal diseases discovered incidentally at death results 
in fully censored data. As Hoel and Walburg have shown (5), isotonic regression 
must be utilized instead of the Kaplan-Meier estimate that is applicable to right 
censored data. Isotonic regression has been applied to estimate the survival-adjusted 
prevalence of pulmonary malignancies as a function of time after exposure in the 
various groups. The results of this isotonic regression reflect the general increase 
of the prevalence with dose and with time after exposure. But, due to the small 
size of most of the experimental groups, no overall estimate of the prevalence as 
a function of dose and time could be inferred. For this reason the simultaneous 
likelihood fit was required, and i t has provided the desired overall estimates. They 
are largely independent of the models chosen as the basis of the simultaneous fit. 
The same is true for the adjusted incidences obtained by integration over the 
prevalences. 
The application of a simultaneous maximum likelihood fit is not new in itself. 
For right censored data a method based on the proportional hazards model has 
existed for some time and has been widely applied (32). No similar treatment had 
earlier been attempted with the fully censored data obtained for nonlethal diseases. 
As exemplified here with the radon studies, the computations require nonlinear 
optimization; such algorithms are widely available. 
A n advantage of the method is the independence from any particular model. I t 
has therefore been applied not only with the proportional hazards models, but also 
with two other models that assume either a dose-dependent time shift of the prev-
alence function or a change of the prevalence function that corresponds to an 
acceleration in time. A l l three models were nonparametric, i.e., no analytical expres-
sion was postulated for the dose or the time dependence of the prevalence. The 
computational procedures are similar for the different models. 
The methods that have been applied here to radon-daughter inhalation studies 
may also prove useful in other inhalation studies. However, they require that the 
pulmonary neoplasms do not appreciably contribute to mortality. While this appears 
to be the case with rats exposed to radon daughters, the condition may be not met 
in other species or with other radioisotopes. 
APPENDIX A: SUMMARY OF RESULTS FOR DIFFERENT TYPES 
OF PULMONARY NEOPLASMS 
Prevalences have been estimated in this article for pulmonary malignancies rather 
than all pulmonary tumors. The reason for this somewhat arbitrary restriction is 
the relatively small number of benign pulmonary tumors that have been found. I t 
was accordingly felt that the advantage of a sharper pathological criterion out-
weighs the gain in statistical accuracy that would accrue from inclusion of the 
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F I G . 8. Prevalance functions for the group exposed to 7000 WLM (4600 WLM/month) from the 
shifted time model for all pulmonary tumors (upper solid line), for pulmonary malignancies (lower solid 
line), for bronchogenic malignancies (broken line), and for bronchoalveolar malignancies (dotted line). | 
benign tumors. There is nevertheless some interest in the discrimination between | 
benign and malign tumors and between malignancies from different cell types. 
A separate analysis of benign tumors is not feasible because benign tumors have! 
been ascertained only in the absence of malignancies of the same cell type. In the! 
whole study, there are only 37 animals with benign tumors and no malignancies; 
there are, in addition, 4 animals where benign tumors have been found simulta-
neously with malignancies in the other cell type. In contrast there were 231 animals 
with pulmonary malignancies. The number with malignancies of both cell types 
was 15. 
In view of the relatively small numbers one cannot expect to establish, with 
statistical certainty, possible differences in the time course and dose dependence 
of the prevalence between malign and benign tumors. Nevertheless, Fig. 8 gives 
an overall comparison of the prevalence obtained for all pulmonary tumors (upper 
solid line), all pulmonary malignancies (lower solid line), bronchogenic malignan-
cies (broken line), and bronchoalveolar malignancies (dotted line). The results are 
from a simultaneous fit of all groups, but Fig. 8 refers only to the large experimental 
group with 7000 W L M (4600 W L M / m o n t h ) . These additional computations have 
been performed with the shifted time model; similar results were obtained with the 
other models. 
The derived time shifts for the different groups and for the different types of 
neoplasms are not given in tabular form but in correlation diagrams in Fig. 9. 
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FIG. 9. Correlation diagrams of the time shifts for all pulmonary malignancies (abscissa) versus those 
for all pulmonary tumors, for bronchogenic malignancies, and for bronchoalveolar malignancies. 
Among all pulmonary malignancies, all pulmonary tumors, and the bronchogenic 
malignancies no systematic difference is apparent. However, one notes that the 
time shifts for bronchoalveolar malignancies at high doses tend to be less than those 
for the other neoplasms. 
Figure 10 compares the adjusted incidences for the different types of pulmonary 
tumors. A decrease at high doses and higher dose rates is apparent only for the 
bronchoalveolar malignancies. This is in line with Fig. 9. 
APPENDIX B: ESSENTIALS OF THE NUMERICAL COMPUTATIONS 
Likelihood Equation for Finite Time Intervals 
Equation (4) for the log-likelihood contains the exact times of death of the 
animals. The actual computations are performed on a discrete time grid with in-
tervals of 30 days or, in the case of the accelerated time model, with a logarithmic 
interval of width 0.08. The data are related to this grid by suitable interpolation. 
In this way the total number of variables to be optimized in a computation is 
reduced to the estimates at 50 grid points for the prevalence function and to 16 
additional variables for the parameters for the individual groups. The log-likelihood 
is then 
/ 
1= 2 [Mi In (Pit,)) + (N, - In (1 - Pit,))}, ( B l ) 
i=l 
where tt (/ = 1 to / ) are the discrete times, TV, is the total number of deaths in 
interval i , and M , is the number of animals with malignancy in interval i. 
The simultaneous solution for several experiments requires, even for the simple 
constraint of monotonicity, an iterative optimization algorithm; the method of steep-
est descent in a computer version, GRGA, of Abadie and Guigou 4, has been applied 
in the present analysis. Wi th the GRGA algorithm it is readily possible to replace 
4 J. Abadie and J. Guigou, Gradient reduit generalise. Internal Report HI-069/02, Electricite de 
France, 1969. 
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the monotonicity constraint by a constraint that leads to smooth curves. The con-
straint actually used was therefore convexity of In (P(t)). Figure 11 uses the example 
of a single but relatively large group for a comparison of the naive estimates (dots), 
the isotonic regression with the exact times of deaths (step function), and the 
computation with convexity constraints (continuous curve) applied only to this 
individual group. 
Joint Likelihood for the Shifted Time Model and the Proportional Hazards Model 
From Eqs. (4) and (5) one obtains the following relation for the log-likelihood 
in the shifted time model: 
L = 2 [2 In (P(ttk + sk) + 2 In (1 - P(tjk + sk))] (B2) 
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F I G . 11. Illustration of the results of maximum likelihood estimation of the prevalence by its application 
to a single large group of animals exposed to an inhalation dose of 7000 WLM. The upper panel 
represents the total number of animals which died in the intervals (blank areas: animals without pul-
monary malignancies; shaded areas: animals with pulmonary malignancies). The lower panel gives the 
estimated prevalence functions (step function from isotonic regression; continuous function from regres-
sion with convexity constraint). Dots are the ratios of the number of animals dead with malignancies 
to the total number of animals dead. 
[symbols as in Eq. (8)] . 
The proportional hazards model leads to a more complicated relation because 
the baseline function in this model is not the prevalence but the related quantity 
cumulative tumor rate, R(t). Wi th the proportional hazards assumption [Eq. (7)] 
and the relation [see Eq. (2)] 
one obtains 
and 
R(t) = - I n (1 - P(t)) (B3) 
PD(t) = 1 - exp( - X(Z)) • R(t)) (B4) 
L = 2 [2 In (1 - exp(-A*.tf(4))) " 2 A * ( B 5 ) 
k=\ /=! y=l 
The same computer program is used for both the shifted time model and the 
accelerated time model; this requires the utilization of the logarithm of time in the 
case of the accelerated time model. Wi th the monotonicity constraint, convergence 
of the optimization procedure is fast and insensitive to the initial estimates. Wi th 
the convexity constraint convergence can be problematic, and the proper selection 
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F I G . 12. The prevalence from the shifted time model as a function of converted time (actual time plus 
the time shift that has been obtained for each group relative to the control group). The upper panel 
represents the pooled total of animals from all groups that died without (blank columns) and with 
(shaded columns) pulmonary malignancies in each interval. Dots are the ratios of the number of animals 
dead with pulmonary malignancies to the total number of animals dead. 
of initial estimates is critical. The initial estimates were usually obtained on the 
basis of the results of the simpler optimization with monotonicity as a constraint. 
Repeated computations with varying starting points have been performed to verify 
the stability of the solutions. 
The maximum likelihood values that were obtained, overall and for the individual 
groups, were within the theoretically expected range of values. Presentation of the 
full data is impractical, but Figs. 12 and 13 are included to illustrate the quality 
of the overall fit. In these figures the individual groups of animals are superimposed 
according to the respective maximum likelihood shifts or acceleration factors. The 
resulting histograms of the total number of animals and the number of animals 
with malignancies are given in the upper panels of the graphs. In the lower panels 
the maximum likelihood prevalence is compared to the ratios of animals with 
malignancy to all animals in the respective intervals. These curves help in judging 
the applicability of the models. 
The standard errors for the raw incidences in Fig. 3 were obtained by using the 
binomial distribution (for 0 observed events the 75% confidence range was used). 
The standard errors for the adjusted incidences were obtained through the standard 
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F I G . 13. The prevalence from the accelerated time model as a function of converted time (time 
multiplied by the acceleration factor that has been obtained for each group relative to the control group). 
The upper panel represents the pooled total of animals from all groups that died without (blank columns) 
and with (shaded columns) pulmonary malignancies. The missing part of the histogram represents 14% 
of all animals included in the computation. Dots are the ratios of the number of animals dead with 
pulmonary malignancies to the total number of animals dead. 
errors of the acceleration factors or through the corresponding parameters for the 
other models. The standard errors of the parameters are obtained on the basis of 
the Fisher statistics as described in a previous application of the optimization 
procedure (41). This is an approximate method, applicable to large numbers of 
animals. The errors are not symmetrical but have been averaged in Table I I except 
for the first group where the asymmetry is particularly large. The parameters and 
their standard errors are given only for the accelerated time model. 
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